CVS Health Co. (NYSE:CVS) Shares Sold by Kiltearn Partners LLP

Kiltearn Partners LLP trimmed its stake in CVS Health Co. (NYSE:CVS) by 9.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 648,368 shares of the pharmacy operator’s stock after selling 68,500 shares during the period. CVS Health accounts for about 4.8% of Kiltearn Partners LLP’s investment portfolio, making the stock its 6th largest position. Kiltearn Partners LLP owned approximately 0.05% of CVS Health worth $29,105,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. State Street Corp boosted its holdings in shares of CVS Health by 3.6% during the 3rd quarter. State Street Corp now owns 56,527,909 shares of the pharmacy operator’s stock worth $3,554,475,000 after buying an additional 1,989,066 shares during the period. Geode Capital Management LLC boosted its holdings in CVS Health by 1.8% during the third quarter. Geode Capital Management LLC now owns 26,361,673 shares of the pharmacy operator’s stock valued at $1,651,997,000 after acquiring an additional 461,569 shares during the period. Pzena Investment Management LLC increased its stake in shares of CVS Health by 49.3% in the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator’s stock worth $880,319,000 after purchasing an additional 6,475,271 shares during the period. Norges Bank bought a new stake in CVS Health during the 4th quarter valued at approximately $839,574,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in CVS Health by 5.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 12,918,949 shares of the pharmacy operator’s stock valued at $579,932,000 after buying an additional 710,281 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

Analysts Set New Price Targets

CVS has been the subject of several research reports. Truist Financial increased their price objective on CVS Health from $60.00 to $76.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Cantor Fitzgerald raised shares of CVS Health from a “neutral” rating to an “overweight” rating in a report on Wednesday, February 12th. Leerink Partners upgraded shares of CVS Health from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $55.00 to $75.00 in a report on Thursday, February 13th. Evercore ISI lifted their target price on CVS Health from $60.00 to $65.00 and gave the stock an “outperform” rating in a research report on Monday, January 27th. Finally, Deutsche Bank Aktiengesellschaft raised CVS Health from a “hold” rating to a “buy” rating and set a $66.00 price target for the company in a report on Tuesday, December 3rd. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and an average target price of $70.39.

Insider Buying and Selling at CVS Health

In related news, Director Michael F. Mahoney purchased 30,000 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were bought at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the purchase, the director now directly owns 39,356 shares in the company, valued at $2,625,045.20. This trade represents a 320.65 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, SVP James David Clark sold 7,513 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the transaction, the senior vice president now directly owns 8,394 shares in the company, valued at $556,941.90. The trade was a 47.23 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.24% of the company’s stock.

CVS Health Stock Up 0.6 %

Shares of NYSE:CVS opened at $67.59 on Friday. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $80.75. The firm has a market cap of $85.22 billion, a P/E ratio of 18.47, a P/E/G ratio of 0.98 and a beta of 0.54. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The company’s 50-day moving average price is $61.83 and its two-hundred day moving average price is $57.60.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. As a group, research analysts forecast that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be given a $0.665 dividend. The ex-dividend date of this dividend is Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 3.94%. CVS Health’s payout ratio is 72.68%.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.